HESCGRO MEDIUM ADVANCES HUMAN EMBRYONIC STEM CELL
RESEARCH.
Millipore Corporation, Billerica, Mass., has announced the
availability of HEScGRO animal component-free medium for human embryonic
stem cell research. HEScGRO medium is the first commercially . . .
QUESTCOR INITIATES QSC-001 CLINICAL PROGRAM.
Questcor Pharmaceuticals, Inc. (AMEX:QSC), Union City, Calif., has
initiatedpatient dosing under its investigational new drug (IND)
application with the U.S. Food & Drug Administration (FDA) . . .
NEURORECOVERY GETS ORPHAN DRUG DESIGNATION.
Neurorecovery, Inc. (NRI), a biopharmaceutical company focused on
treatments for peripheral neuropathies, has announced that its request
for orphan drug designation of 4-Aminopyridine has been . . .
MEDICINOVA INITIATES PHASE II TRIAL FOR MN-221.
MediciNova, Inc., San Diego, Calif., a biopharmaceutical company
that is publicly traded on NASDAQ (Nasdaq:MNOV) and the Hercules Market
of the Osaka Securities Exchange (Code Number: 4875), has . . .
CELLDEX/LUDWIG INST. FORM RESEARCH COLLABORATION.
Celldex Therapeutics, Inc. and the international Ludwig Institute
for Cancer Research (LICR) have announced a multi-year clinical research
collaboration focusing on a series of tumor-associated . . .
SAMARITAN'S SP-10 HAS GOOD ANTIVIARL ACTIVITY WITH
HCV.
Samaritan Pharmaceuticals Inc. (AMEX:LIV), Las Vegas,a developer of
innovative drugs, has announced that an in-vitro study conducted on its
oral entry inhibitor SP-10 by the National Institutes of . . .
$5 BILLION KNEE IMPLANT MARKET GETS BOOST FROM WOMEN.
Millennium Research Group (MRG), Waltham, Mass., has conducted a
detailed analysis of the US large-joint implant market. The analysis
finds that one of the latest trends in the US knee implant . . .
NVENTA UPDATES DEVELOPMENT STRATEGY ON HSPE7.
Nventa Biopharmaceuticals Corporation (TSX:NVN), San Diego, has
provided an update on HspE7, the company's investigational
therapeutic vaccine candidate for human papillomavirus (HPV)- . . .
OXIGENE GETS POSITIVE RESULTS OF PHASE II STUDY OF CA4P.
OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), Waltham, Mass., has
completed a Phase II Study in patients with advanced imageable
malignancies. This was a randomized open-label study of intravenous . . .
INFLAMMATORY ENZYNE LP-PLA2 PREDICTS RECURRENT STROKE.
diaDexus, Inc., South San Francisco has announced the publication
of a study showing that lipoprotein-associated phospholipase A2 (Lp-
PLA2), a cardiovascular-specific inflammatory enzyme . . .
OSCIENT COMPLETES ENROLLMENT IN PHASE IV OF FACTIVE
TABLETS.
Oscient Pharmaceuticals Corporation (Nasdaq: OSCI), Waltham, Mass.,
has completed enrollment in its Phase IV post-marketing trial for its
fluoroquinolone antibiotic, FACTIVE (gemifloxacin mesylate) . . .
SYNVISC IMPROVES OSTEOARTHRITIS PAIN.
Genzyme Corporation (NASDAQ:GENZ), Cambridge, Mass. has announced
that preliminary results from a new study indicate that patients using
Synvisc (hylan G-F 20) through a single-dose regimen . . .
MEMORY PHARMACEUTICALS COMPLETES ENROLLMENT FOR MEM
1003.(Clinical report)
Memory Pharmaceuticals Corp. (NASDAQ:MEMY), Montvale, N.J., has
completed enrollment in its ongoing Phase 2a trial of MEM 1003 in
patients with acute mania in bipolar disorder. The company now . . .
BRONCHIAL THERMOPLASTY ONE "TOP 10 INNOVATIONS" OF
2007.
Asthmatx, Inc., Mountain View, Calif., a medical device company
that has developed a catheter-based procedure for the treatment for
asthma, has announced that bronchial thermoplasty, an . . .
IDM PHARMA SUBMITS NDA FOR JUNOVAN OSTEOSARCOMA
TREATMENT.
IDM Pharma (NASDAQ:IDMI), Irvine, Calif., has submitted an
electronic New Drug Application (NDA) to the U.S. Food and Drug
Administration (FDA) for Junovan (mifamurtide for injection), . . .
FDA GRANTS ORPHAN DRUG DESIGNATION FOR DROXIDOPA.
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), Charlotte,
N.C., has announced that the U.S. Food and Drug Administration (FDA) has
granted Orphan Drug designation to its drug candidate . . .
ANESIVA FILES NDA FOR ZINGO TO REDUCE PAIN FROM NEEDLES.
Anesiva, Inc. (NASDAQ:ANSV), has filed a New Drug Application (NDA)
with the FDA for marketing clearance of Zingo(TM) to treat the pain
associated with venous access procedures in children. As part . . .
AVAA WORLD HEALTH LAUNCHES CLINICAL TRIAL FOR NEUROSKIN.
avVaa World Health Care Products Inc. (BULLETIN BOARD: AVVW) , a
global biotechnology company offering therapeutic, natural skin and
health care products, has announced that Dr. Mark Alden, avVaa . . .
INNOVIVE ENROLLS FOR PHASE I OF INNO-305 PEPTIDE
IMMUNOTHERAPY.
INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH), a biopharmaceutical
company headquartered in Manhattan, announced today that a Phase I
clinical trial investigating INNO-305 in acute myelogenous . . .
COLAZAL "FOOD EFFECT" APPLICATIOM GRANTED FDA
APPROVAL.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), Raleigh, N.C., has
announced that the U.S. Food and Drug Administration approved a
supplemental new drug application which provides for changes to . . .
|
|